
1

# Case recognition and case definition in the multi country outbreak

Prof Chloe Orkin
Queen Mary University of London

I have no disclosures related to monkeypox



#### Global picture - slide will definitely be out of date



Total cumulative number of cases

53K

VIEW MORE >>

Number of countries reporting at least one case

125

Total cumulative number of cases in WHO European Region 22.9K Total cumulative number of deaths

18


VIEW MORE >>

Total cumulative number of cases in WHO Region of the Americas

29.3K

VIEW MORE >>

Total cumulative number of cases in WHO African Region **521** 



#### **Key features WHO (Dataset n= 27K)**



- 98% male
- 95% GBMSM (1.7% bisexual)
- Median age 36
- 1.8% female
- Most commonly reported setting: party with sexual contact
- Children(<17): 0.6%
- PWH: 45%
- 313 HCW (not all are occupational)

#### Case profiles

As of September 02 2022

	Reporte	d values <sup>1</sup>	Unknown or Missing Volus
	Yes	No	Unknown or Missing Value
Men who have sex with men	11923 (95.2%)	606 (4.8%)	33442
HIV-Positive	5576 (44.9%)	6833 (55.1%)	33562
Health worker	313 (4.2%)	7069 (95.8%)	38589
Travel History	1212 (27.9%)	3127 (72.1%)	41632
Sexual Transmission	7822 (91.0%)	777 (9.0%)	37372
Hospitalised <sup>2</sup>	1549 (8.4%)	16928 (91.6%)	27494
ICU	9 (0.1%)	8072 (99.9%)	37890

#### **Declining numbers globally**




- Overall global decline
- Growing fraction of people with no MSM contact

#### Monkeypoxtally @Monkeypoxtally · 2d

This is the third week in a row where we see **monkeypox cases decline** globally and we are seeing a plateauing/ slowing down trend in the last 6 weeks around 5,000-6,000 weekly **cases**.

This week we saw the biggest decline in cases among the last 3 weeks



https://worldhealthorg.shinyapps.io/mpx\_global

# Case Definitions May 2022

 Expanded to specify at risk group as sexually active MSM, GBMSM


#### Clinical symptom/sign case definitions May 2022

	World Health Organization	EUROPEAN CENTRE FOR AND CONTROL	ODC	UK Health Security Agency
Rash description	An unexplained acute rash or one or more acute skin lesions	An unexplained rash on any part of the body	Deep-seated,well-circumscribed lesion, central umbilication; lesion progression through specific sequential stages—macules, papules, vesicles, pustules, scabs	An unexplained rash on any part of their body
Fever	>38.3°C (101°F)	Fever (usually > 38.5°C)	Not mentioned	>38.5°C
Lymphadenopathy	Lymphadenopathy	Generalised or localised	Not mentioned	Lymphadenopathy
Other	intense headache, back pain, myalgia and intense asthenia	headache,-backache, and fatigue	Not mentioned	chills, headache, exhaustion, Myalgia Back pain Asthenia

#### Clinical symptom/sign case definitions May 2022

	WHO	ECDC	CDC	UKH\$-
Rash description	one skin lesions	An unexplained rash on any part of the body	Deep-seated, well-circums lesion, central umbili progression thre sequential papul rules, scabs	unexplained rash on any part of their body
Fever	>38.3°C (101°F)	vally >	lesion, central umbiliprogression thresequential papul rules, scabs  tioned  Not mentiones	>38.5°C
Lymphadenopathy	Lymphadenopathy	Tieslor	tioned	Lymphadenopathy
Other	intense hear myale asthenia	headache, backache, and fatigue	Not mentioned	chills, headache, exhaustion, lgia Back pain


#### Data covering April 27th to June 24th



DRIGINAL ARTICLE

#### Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022

John P. Thornhill, M.D., Ph.D., Sapha Barkati, M.D., Sharon Walmsley, M.D., Juergen Rockstroh, M.D., Andrea Antinori, M.D., Luke B. Harrison, M.D., Ph.D., Romain Palich, M.D., Ph.D., Achyuta Nori, M.D., Iain Reeves, M.D., Maximillian S. Habibi, M.D., Ph.D., Vanessa Apea, M.D., M.P.H., Christoph Boesecke, M.D., Linos Vandekerckhove, M.D., Ph.D., Michal Yakubovsky, M.D., Elena Sendagorta, M.D., Ph.D., Jose L. Blanco, M.D., Ph.D., Eric Florence, M.D., Ph.D., Davide Moschese, M.D., Fernando M. Maltez, M.D., Ph.D., Abraham Goorhuis, M.D., Ph.D., Valerie Pourcher, M.D., Ph.D., Pascal Migaud, M.D., Sebastian Noe, M.D., Claire Pintado, M.D., Fabrizio Maggi, M.D., Ph.D., Ann-Brit E. Hansen, M.D., Ph.D., Christian Hoffmann, M.D., Ph.D., Jezer I. Lezama, M.D., Ph.D., Cristina Mussini, M.D., AnnaMaria Cattelan, M.D., Keletso Makofane, M.P.H., Ph.D., Darrell Tan, M.D., Ph.D., Silvia Nozza, M.D., Ph.D., Johannes Nemeth, M.D., Marina B. Klein, M.D., and Chloe M. Orkin, M.D. for the SHARE-net Clinical Group\*





#### 4 West London clinics Data covering 14-25/5/22



#### Single south London clinic 13 May and 1 July 2022

thebmj

covid-19

Research •

Education - News & Views -

Campaigns ~

lobs ~

#### Research

Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series

BMJ 2022; 378 doi: https://doi.org/10.1136/bmj-2022-072410 (Published 28 July 2022)


Cite this as: BMJ 2022;378:e072410

Aatish Patel , infectious diseases registrar,



#### May 11 to June 29, 2022.

#### THE LANCET



Submit Article Log in Register Subscribe Claim





#### Demographics

	Global <sup>2</sup> N=528	West London <sup>1</sup> N=54	South London <sup>3</sup> N=197	Spain <sup>4</sup> N=181
Male	100%	100%	100%	97% (3% female)
MSM	98%	100%	99.5%	92%
Age	38	41	38	37
White	75%	48%	N/R	N/R
PWH	41%	24%	36%	40%
PWH undetectable (VL<200c/mL)	97%	85%	79%	N/R
PWH CD4 count	668	500	664	N/R
Prior small pox vaccination	9%	N/R	N/R	18%

	Global <sup>2</sup> N=528	West London <sup>1</sup> N=54	South London <sup>3</sup> N=197	Spain <sup>4</sup> N=181
Suspected sexual transmission	95%	96%	96%	97%
Number of partners (median)	5	<b>&gt;&gt;5</b> %	N/R	6.5
Travel history	28%	46%	27%	14%
Sex on site venue	32%	N/R	N/R	N/R
Known sexual contact with monkeypox	26%	2%	26%	26%
Chemsex	20%	N/R	N/R	31%
Household contact	1%	N/R	N/R	3%
STI	29%	25%	31.5%	17%

# Where did they attend?

The health setting of initial presentation included sexual health, HIV clinics, emergency departments, and dermatology clinics, primary care and private clinics.

# Incubation period

Median incubation period was 7 days (range, 3 to 20)

# Clinical Presentation

95% of the persons presented with a rash

#### Where:

• 73% had anogenital lesions, 55% trunk, arms, or legs the face (25%); and the palms and soles (10%).

#### How many lesions?

- Most (64%) had < 10 lesions</li>
- 54 had a single genital lesion (10%).


#### What does rash look like:

- A wide spectrum including macular, pustular, vesicular, and crusted lesions, and lesions in multiple phases were present simultaneously.
- 58% had lesions that were described as vesiculopustular.

#### Rash Descriptors


	Global <sup>2</sup> N=528	West London <sup>1</sup> N=54	South London <sup>3</sup> N=197	Spain <sup>4</sup> N=181
Anogenital rash	73%	94%	88%	78%
Description	58% vestibulo- pustular	Multiple stages	Multiple stages	Pustular 90%
Number of lesions	2-10 in 64%	'Multiple' in 89%	2-10 in 51%	92% <20
Single lesion presentations	10%	11%	11%	N/R
Face	25%	20%	36%	N/R
Body (trunk/limbs)	55%	40%	73%	57%
Hands /feet	10%	20%	28%	60%

A) Evolution of cutaneous lesion in an individual with Human Monkeypox infection.
Al-A3 show facial lesions, Bl-B3 shows evolution of a penile lesion and Cl-2 shows a lesion on the forehead. PCR status is indicated where available.















Day -4 Sexual Contact, MSM Condomless

Day 4-6
Feeling unwell,
development of additional lesions

Day 21
Follow up #1
facial PCR negative, genital lesions PCR positive

Day 0
Single genital lesion
Treated with i.m penicillin as suspected Syphilis,

Day 11
Confirmed Monkeypox facial and genital lesions PCR positive

Day 28
Follow up #2
genital lesions PCR negative

Figure 21: Penile/scrotal lesions in individuals with Human Monkeypox infection.




# \*\*New\*\* mucosal presentations

- 41% had mucosal lesions
- Anorectal mucosa reported as the presenting symptom in 61 persons
- Oropharyngeal symptoms were reported as the initial symptoms in 26 persons
- In 3 persons, conjunctival mucosa
- Penile oedema and urethritis reported by other groups (BMJ Patel group)

#### Mucosal lesions

	Global <sup>2</sup> N=528	West London <sup>2</sup> N=54	South London <sup>3</sup> N=197	Spain <sup>4</sup> N=181
Mucosal lesions	41%	<b>??</b> ?	??	35%
Oral lesions	5% (as 1 <sup>st</sup> symptom)	7%	16.8%	25%
Anal lesions	12% (as 1st symptom)	<b>.</b> 55	36%	25%
Conjunctival lesions	0.2%	N/R	N/R	N/R
Urethral lesions/ Penile oedema	N/R	N/R	15.7% 31 penile oedema	8%




B) Oral and perioral lesions in individuals with Human Monkeypox infection.



A. perioral umbilicated lesions. **B.** Perioral vesicular lesion, day 8, PCR positive. **C.** Ulcer left corner of the mouth, day 7, PCR positive. **D.** Tongue ulcer. **E.** Tongue lesion, day 5, PCR positive. **F, G, H.** Pharyngeal lesions, day 0, 3 and 21 respectively. PCR positive on day 0 and 3 and negative on day 21.

Thornhill J N Engl J Med 2022; 387:679-69





F. Umbilicated perianal lesion, day 3. PCR positive. G. Umbilicated perianal lesions, day 3. PCR positive. H. Perianal ulcer, day 2. PCR positive

	Global <sup>2</sup> N=528	West London <sup>1</sup> N=154	South London <sup>3</sup> N=197	Spain <sup>4</sup> N=181
Fever	62%	67%	62%	72%
Headache	27%	N/R	25%	53%
Myalgia	31%	30%	32%	N/R
Lymphadenopath y	56%	56%	58%	85%
Arthralgia	N/R	N/R	10%	N/R
Fatigue	41%	67%	23%	N/R
Low Mood	10%	N/R	N/R	N/R

#### Admissions / complications

	Global <sup>2</sup> N=528	West London <sup>1</sup> N=54	South London <sup>3</sup> N=197	Spain <sup>4</sup> N=181
Admissions for medical reasons	57 (11%)	9%	20 (10.%)	2 (<2%) (bacterial cellulitis)
Infections	18	6 (11%)	3 groin 2 tonsillar	6 (3%)
Rectal complications	21	? 5 rectal cellulitis	8	No admissions (25% proctitis)
Oral lesion complications	5	N/R	2	Oral ulcers and tonisllitis (no admissions)
Penile swelling	N/R	7%	5	8% (15)
Other	Epiglottitis	Ano-genital cellulitis	Urinary retention	Paraphimosis 15(8%)
	Myocarditis x 2	Dissseminated	Paraphimosis	Bacterial skin Abscess 6 3%
	AKI 2	infection	Conjunctival lesion 2	Exanthem 4%
			Rectal perforation 1	
			Disseminated lesions 1	
Received treatment	5%	2% (n=1)	Not mentioned	6
Deaths	0	0	0	0




Figure 15: Evolution of nasal lesions in an individual with Human Monkeypox infection first presented with a single nasal lesion. A1-A5 show evolution of a nasal lesion, B shows a single forearm lesion. PCR status is indicated where available.















Day 3
Fever and development
of additional forearm lesion

Day 9
Worsening of the lesion start of antibiotic therapy

Day 19
Nasal swab persisting positive
Second dose of Cidofovit/probenecid

Day 0
Single nasal lesion
with cervical lymphadenopathy

Day 7
Confirmed Monkeypox nasal lesion PCR positive

Day 13
Follow up visit
Admission and treatment
with cidofovir/probenecid

Day 21
Patient discharged
Nasal wound improved

Thornhill J N Engl J Med 2022; 387:679-69



Figure 23: Bodily Skin lesions in individuals with Human Monkeypox infection.





■ 41% (218) were PWH




- Median CD4 680 cells/MM<sup>3</sup>
- 97% VL <200 c/mL and on ART</li>
- No differences in natural history or outcomes observed across entire cohort (see table in supplement)
- We reviewed site of presentation, nature. site and type of rash, extent of rash, mucosal presentations, systemic symptoms, admissions, complications
- However, of the three most significant complications (epiglottitis (1), myocarditis (2), 2 were PWH

## Semen

Found in 29/32 of samples tested

## HIV: 40 years of activism drove progress



# New monkeypox activists

#### Harun Tulunay @HarunTulunay · 27/08/2022

I was lucky to have support and understanding from @Positively\_UK but government need to support people who are isolating with #monkeypox financially and legally.

islingtontribune.co.uk/article/monkey...

Calls for extra support for those with virus

Friday, 26th August — By Anna Lamche






pinknews.co.uk Man who shared monkeypox experience flooded with disgusting, homophobic abuse




### 'When will you include include mucosal and single lesions CDC, WHO, ECDC?'

Activism to change case definitions



AIDS2022 Conference, Monkeypox session, July, Montreal Canada



#### 'When will you include include mucosal and single lesions CDC?'

#### New York Times

Dr. Orkin is president of the Medical Women's Federation, past president of the British H.I.V. Association and a governing council member of the International AIDS Society. "I've got a loud voice," she said, "and I'm still finding it difficult to get a response."

Senior members of the W.H.O. responded to Dr. Orkin on Aug. 2, asking to discuss the cases that she and her colleagues had described. The C.D.C. did not reply to Dr. Orkin but added rectal pain and bleeding, along with other new symptoms, to its guidance to clinicians on Aug. 5.

#### Dear Dr Walensky... CDC



Chloe Orkin @profchloeorkin · 6d

Thanks for sharing your (great) story again @gOingmad.

The @CDCgov case definition still does not specify oral lesions.

I remain concerned this will lead to misdiagnosis.

People must be tired of me going on but effective activism is incessant advocacy! @dr demetre @CDCDirector



"Case recognition is vital, and we haven't been equipped to actually recognize the disease," @profchloeorkin told me back in July.

(Story here: bloomberg.com/news/articles/...)

Great to see the WHO is now broadening its case definitions. twit...



#### **Expanded case definition for monkeypox infection**



To: ○ rwalensky@cdc.gov; Cc: ○ Carlos del Rio, MD >>

Saturday, 23 July 2022 at 15:27

To protect your privacy, some external images in this message were not downloaded.

Download external images

Dear Dr Walensky.

I am a clinician in London, past Chair of the British HIV Association and the senior author for the recently published large global case series on monkeypox infection published on Thursday in the NEJM.

#### https://www.nejm.org/doi/full/10.1056/

In our large global case series n=528 from 16 countries, we have described first presentations which are not included in the global case definitions. One example is single genital lesions (~10%) . But much more important were primary mucosal presentations with no other skin lesions.

Ano-rectal involvement as the first symptom was reported in 61 people (11.5%) associated with severe anorectal pain, proctitis, tenesmus and/or diarrhoea. Ano-rectal symptoms sometimes led to admission for pain control.

Oropharyngeal symptoms were the initial presentation reported in 26 individuals with pharyngitis, painful swallowing, epiglottitis, and oral or tonsillar lesions. Some required hospitalisation. Conjunctival mucosa and nasal lesions also occurred.

Managing these oral and rectal lesions has necessitated admission and we found these were amongst the most common causes of admission.

We found that people presented to a wide range of places including GPs and emergency departments. These clinicians are less likely to recognise monkeypox than clinicians at sexual health and HIV clinics making the case definition especially important.

In our paper the authors called for an expanded case definition to assist with case recognition to include single lesions, and most importantly, to include mucosal primary presentations without other skin lesions.



Chloe Orkin @profchloeorkin · 1h

The @CDC definition still does not reference oral lesions even after the change on 5/8/22

This is an important omission given the severe tonsillar presentations which can require hospitalisation

@JohnPThornhill @Boghuma @apoorva\_nyc @dr\_demetre

bit.ly/3PGg7js



# Case definitionschanged



#### Clinical case Definitions August 2022- paraphrased

	World Health Organization	EMOTE AN CRATE TO A CREEKE THE AT THE		4() UK Health Security Agency
Rash description	An explained acute rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body.	An unexplained rash on any part of the body	Lesions are firm or rubbery, well-circumscribed, deep-seated, and often develop umbilication (resembles a dot on the top of the lesion). Lesions typically develop simultaneously and evolve together on any given part of the body. The evolution has four stages—macular, papular, vesicular, to pustular—before scabbing over and desquamation.	Unexplained rash on any part of their body Lesions, including but not limited to: genital, ano-genital lesions
Fever/prodrome lymphadenopathy	Acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.	Fever (usually > 38.5°C)	Fever and other prodromal symptoms (e.g., chills, lymphadenopathy, malaise, myalgias, or headache) can occur before rash /after rash/ not occur	Febrile prodrome consists of fever ≥ 38°C, chills, headache, exhaustion, myalgia, arthralgia, backache, lymphadenopathy.
Mucosal lesions	Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Anorectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.	Not specifically mentioned	Rectal symptoms (purulent or bloody stools, rectal pain, or rectal bleeding).  Mouth lesions	Oral lesion(s) – for example, ulcers, nodules Proctitis – for example anorectal pain, bleeding



## Thank you